MSF reacts to recent results of the Strategic Timing of Antiretroviral Treatment (START) study.“We should no longer squander an opportunity to offer treatment to a person living with HIV who is not yet seriously ill, because our experience shows that a third of these people will never come back to get treatment.” -Dr. Helen Bygrave, HIV medical advisor in MSF Southern Africa Medical Unit. http://bit.ly/1VAylCu